Regeneron Forms Radiopharma Partnership with Telix, Potentially Worth Over $2.1 Billion
REGN sits 57% above its 52-week low of $476.487.
Summary
Regeneron Pharmaceuticals has announced a strategic radiopharmaceutical partnership with Australia's Telix Pharmaceuticals. The collaboration involves co-developing and co-commercializing therapies, with costs and profits split equally. Telix will receive an upfront payment of $40 million for four initial programs, with the agreement potentially reaching over $2.1 billion in development and commercial milestone payments plus low double-digit royalties. This partnership expands Regeneron's pipeline into the radiopharmaceutical space, leveraging Telix's development and manufacturing capabilities with Regeneron's antibody discovery platforms. This is a material strategic move that could drive future growth and diversify Regeneron's therapeutic offerings.
At the time of this announcement, REGN was trading at $749.36 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $79.2B. The 52-week trading range was $476.49 to $821.11. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.